As the fourth quarter of 2025 begins, Shiba Inu (SHIB) is seeing a new wave of momentum courtesy of increasing speculation and token burns. But while Shiba Inu relies on hype, real buzz surrounds Mutuum Finance (MUTM), a utility-oriented DeFi token that most analysts are now saying is the top crypto to invest in. With […]As the fourth quarter of 2025 begins, Shiba Inu (SHIB) is seeing a new wave of momentum courtesy of increasing speculation and token burns. But while Shiba Inu relies on hype, real buzz surrounds Mutuum Finance (MUTM), a utility-oriented DeFi token that most analysts are now saying is the top crypto to invest in. With […]

Shiba Inu Price Prediction: SHIB Rallies as Q4 2025 Kicks Off, While Mutuum Finance (MUTM) is Named the Top Crypto to Buy

2025/10/05 01:30
4 min read
For feedback or concerns regarding this content, please contact us at [email protected]

As the fourth quarter of 2025 begins, Shiba Inu (SHIB) is seeing a new wave of momentum courtesy of increasing speculation and token burns. But while Shiba Inu relies on hype, real buzz surrounds Mutuum Finance (MUTM), a utility-oriented DeFi token that most analysts are now saying is the top crypto to invest in. With its presale Stage 6 already over 55% sold, and backed by 16,750+ holders and $16.8 million+ raised, Mutuum Finance is being supported by its strong foundation of dual lending protocols, real-yield tokenomics, and non-custodial infrastructure. In a market tired of hype moving towards substance, Mutuum Finance stands to have upside leadership over SHIB in the subsequent market cycle.

Shiba Inu (SHIB) Holds Key Rebound Level, Can Bulls Seize Control?

Shiba Inu (SHIB) currently trades at a very significant technical level of around $0.0000115, a level that has had a proven track record of holding firm as a good support in past market cycles. With exchange reserves at a near two-year low, pressure to sell appears to be easing, strengthening the argument for a potential rebound from here. If SHIB can sustain this level, an extended rally could ignite fresh momentum into Q4. 

A breakdown below support, however, may bring additional downside targets. While investors debate the next move for SHIB, there are also plenty of long-term players looking at prospects in emerging DeFi project Mutuum Finance (MUTM) that’s generating increasingly higher degrees of interest ahead of the next bull cycle.

Mutuum Finance Presale Frenzy Gains More Momentum

Mutuum Finance (MUTM) sees sharp progress in round six of presale as demand goes through the roof and the project raises over $16.8 million. Early investors are preparing themselves for potentially astronomical profits when the token is released for sale on the open market. Mutuum Finance is also creating new waves for a healthily flourishing DeFi ecosystem with the projected launch of a USD-backed stablecoin on the Ethereum blockchain.

In order to fulfill its promise of investor confidence and platform security, Mutuum Finance has signed up with CertiK to roll out a $50,000 USDT Bug Bounty Program. The initiative is calling coders, white-hat hackers, and security researchers to participate to discover bugs rewarded in terms of severity ranging from low and minor to high and critical. The project is supporting community interaction with an early bird $100,000 giveaway, offering an extra motivation to join the presale.

Mutuum Finance Prepares to Launch Lending & Borrowing Protocol

Mutuum Finance publicly announced its preparations for launching its lending and borrowing protocol, an enormous development of its decentralized finance abilities. Scheduled for release on the Sepolia Testnet within V1 in Q4 2025, the protocol will introduce fundamental aspects such as liquidity pool, mtToken, debt token, liquidator bot, and other key features. Supporting ETH and USDT initially for lending, borrowing, and collateral purposes, the platform is focused on a user-friendly and multi-purpose DeFi solution. 

Mutuum Finance protocol architecture is founded on close-order book topology, which will be reducing market risk and constraining illiquidity. Determining the primary parameters of liquidation levels, close-level conditions, and liquidator incentives is to make lending safe and stable. LTV and liquidation ratios are also calculated dynamically in relation to asset volatility, and riskier assets will be imposing more stringent lending terms. In addition to that, multipliers risk-weighted are employed across asset classes in a way as to maximize utmost aggregate resilience, security, and stability with varying market conditions.

Shiba Inu’s Q4 confirms that hype is still alive, but for the investor looking at real utility and enormous potential, Mutuum Finance (MUTM) wins hands down. With the tokens still at just $0.035, over 55% of presale already sold in stage 6, $16.8 million raised, and 16,750+ early adopters onboard, MUTM is building a crushing DeFi platform that has nothing to do with hype. Its two lending protocols, addition of stablecoin, and advanced risk architecture place it with the potential to outperform SHIB, and become one of the top-performing cryptos of the next market cycle.

For more information regarding Mutuum Finance (MUTM) please use the following links:

Website: https://mutuum.com/

Linktree: https://linktr.ee/mutuumfinance

Market Opportunity
SHIBAINU Logo
SHIBAINU Price(SHIB)
$0.000005397
$0.000005397$0.000005397
+1.06%
USD
SHIBAINU (SHIB) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09